公开(公告)号：US20240082154A1

公开(公告)日：2024-03-14

申请号：US18491953

申请日：2023-10-23

Applicant: Osaka University ,  Cuorips Inc

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Yoshiki Sakai ,  Yasuhiro Yanagi

IPC: A61K9/127 ,  A61K31/4406

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K31/4406

Abstract: The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.

公开(公告)号：US20230032285A1

公开(公告)日：2023-02-02

申请号：US17785245

申请日：2020-12-10

Applicant: CUORIPS INC.

Inventor： Masanori TANAKA ,  Noriko UMEDA ,  Naoko TERAO ,  Atsuko WAKIMURA ,  Tsuyoshi ISHIKAWA ,  Nobu MIYAKAWA

IPC: F24F3/167

Abstract: The present invention provides a facility capable of efficiently performing work while maintaining the cleanliness of a location where an article is manufactured, when manufacturing of the article and other work are performed in parallel concurrently; and an implementation method for manufacturing an article by using the facility. The facility comprises a clean room 1, multiple work booths 2 provided inside the clean room 1 and each comprising an entrance and exit, and barrier sections provided along entrances and exits of the multiple work booth 2 and configured to prevent airflow from the outside to the inside through the entrances and exits. The area inside each of the multiple work booths 2 has the same grade of cleanliness as the area that is outside the multiple work booths 2 but is inside the clean room 1.

公开(公告)号：US20240197753A1

公开(公告)日：2024-06-20

申请号：US18283585

申请日：2022-03-25

Applicant: OSAKA UNIVERSITY ,  CUORIPS INC.

Inventor： Yoshiki SAWA ,  Shigeru MIYAGAWA ,  Yoshiki SAKAI ,  Yasuhiro YANAGI

IPC: A61K31/559 ,  A61K9/06 ,  A61K9/16 ,  A61K9/70 ,  A61K47/42 ,  A61P9/04

CPC classification number: A61K31/559 ,  A61K9/06 ,  A61K9/1647 ,  A61K9/7007 ,  A61K47/42 ,  A61P9/04

Abstract: An object is to provide a pharmaceutical composition that improves cardiac function when administered during coronary artery bypass surgery for ischemic cardiomyopathy. A pharmaceutical composition for improving cardiac function comprising: (A) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 10000 to 30000; and (B) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 40000 to 60000.